{'fraction_non_alphanumeric': 0.05060858424087124, 'fraction_numerical': 0.051889814221652786, 'mean_word_length': 5.1015625, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
AB0453 Response to TOCILIZUMAB in Rheumatoid Arthritis is not Influenced by the Body Mass Index of the Patient

Objectives To assess relationship between body mass index (BMI) and efficacy of tocilizumab (TCZ) in rheumatoid arthritis (RA) patients. Methods We conducted a retrospective study of the use of TCZ in patients with RA followed by five academic hospitals in France. The efficacy of TCZ was evaluated at 6 months by the European League Against Rheumatism (EULAR) response. Univariate and multivariate logistic regressions were performed adjusting for age, sex, disease duration, C-Reactive protein, erythrocyte sedimentation rate, presence of erosive lesions, rheumatoid factor and anti-citrullinated peptide antibodies positivity, disease duration, disease activity score, concomitant therapy by disease modifying anti-rheumatic drugs. Results Among 222 RA patients treated by TCZ, 58.5% had a low BMI<25kg/m2, 26% had an intermediate BMI between 25-30kg/m2, and 15.5% had a high BMI>30kg/m2. No significant association between BMI and response to TCZ at 6 months was found after adjustment for potential confounding factors (OR 0.47; 95%CI [0.18; 1.23], p=0.12 and OR 1.56 95%CI [0.42; 5.67], p=0.49 for BMI=25-30kg/m2 and BMI>30kg/m2 respectively compared to BMI<25kg/m2). Conclusions Response to TCZ in RA patients is not influenced by the baseline BMI, in contrast to anti-TNF drugs. Future research should assess these differences prospectively for better comparisons. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.1508